Key result
Applying 2017 ACC/AHA guidelines increases estimated hypertension prevalence by ~181% vs JNC-7 in a Saudi cohort.
Why the study?
To assess the effect of the 2017 ACC/AHA hypertension guideline on the prevalence of elevated blood pressure, hypertension, initiation of antihypertensive treatment, and adherence to blood pressure targets in the Saudi population.
Does the application of the 2017 ACC/AHA guideline increase the prevalence of hypertension and recommended treatment compared to the JNC-7 guideline in Saudi adults?
Cross-Sectional (n=10,799)
Does the application of the 2017 ACC/AHA guideline increase the prevalence of hypertension and recommended treatment compared to the JNC-7 guideline in Saudi adults?
Effect estimate: Difference 26.28%
Absolute Event Rate: 40.77% vs 14.49%
The 2017 ACC/AHA guideline significantly increases the prevalence of hypertension compared to JNC-7, with a smaller impact on the proportion of patients recommended for antihypertensive medication.
Raises hypertension prevalence estimates threefold in Saudi adults; leaves open whether 2017 ACC/AHA thresholds improve outcomes or increase overdiagnosis.
OBJECTIVES: To assess the effect of the 2017 American College of Cardiology and the American Heart Association (ACC/AHA) hypertension guideline on the prevalence of elevated blood pressure (BP) and hypertension and the initiation of antihypertensive treatment, as well as the level of adherence to the BP target in the Saudi population. DESIGN: A cross-sectional study. PARTICIPANTS: A total of 10 799 adults (≥18 years old), with three BP readings during 2017-2020 from the Saudi Biobank was used. PRIMARY OUTCOME: Hypertension was defined using three sources: the Joint National Committee 7 Blood Pressure Guideline (JNC-7) guideline (systolic BP (SBP)≥140 or diastolic BP (DBP)≥90 mm Hg), the 2017 ACC/AHA guideline (SBP≥130 or DBP≥80 mm Hg) and a self-reported hypertension diagnosis. RESULTS: The prevalence of hypertension, according to the JNC-7 guideline, was 14.49% (95% CI 14.37 to 14.61), and the 2017 ACC/AHA, 40.77% (95% CI 40.60 to 40.94), a difference of 26.28%. Antihypertensive medication was recommended for 24.84% (95% CI 24.69 to 24.98) based on the JNC-7 guideline and 27.67% (95% CI 27.52 to 27.82) using the 2017 ACC/AHA guideline. Lifestyle modification was recommended for 13.10% (95% CI 12.47 to 13.74) of patients with hypertension who were not eligible for a pharmacological intervention, based on the 2017 ACA/AHA guideline. For patients with prescribed antihypertensive medication, 49.56% (95% CI 45.50 to 53.64) and 27.81% (95% CI 24.31 to 31.59) presented with a BP reading above the treatment goal, based on the 2017 ACA/AHA and JNC-7 guidelines, respectively. Using the two definitions, the risk factors were older age, male gender, diabetes diagnosis, increased body mass index, waist circumference and waist-to-hip ratio. CONCLUSIONS: According to the 2017 ACC/AHA guideline, the prevalence of hypertension has increased significantly, but there was only a small increase in the proportion of patients recommended for antihypertensive treatment. A large proportion of patients with prescribed antihypertensive medication, had a BP above the target. Unless public health prevention efforts are adopted, the increased prevalence of elevated BP and hypertension will increase cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Alyabsi et al. (2020) conducted a cross-sectional in Hypertension (n=10,799). 2017 ACC/AHA guideline vs. JNC-7 guideline was evaluated on Prevalence of hypertension (Difference 26.28%). Application of the 2017 ACC/AHA guideline compared with the JNC-7 guideline increased the estimated prevalence of hypertension from 14.49% to 40.77% in a Saudi cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: